Sutro Biopharma (STRO) Cash from Financing Activities (2017 - 2025)

Sutro Biopharma has disclosed Cash from Financing Activities across 9 years of filings, most recently posting -$64000.0 for Q4 2025.

• Cash from Financing Activities for Q4 2025 came in at -$64000.0, down 166.67% year-over-year; the trailing twelve-month figure through Dec 2025 was $44000.0 (down 99.95% YoY), and the FY2025 annual result was $44000.0, down 99.95% from the prior year.
• Cash from Financing Activities came in at -$64000.0 for Q4 2025 at Sutro Biopharma, down from $102000.0 in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $137.7 million in Q2 2023 to a low of -$5.7 million in Q3 2023.
• The 5-year median for Cash from Financing Activities is $633000.0 (2021), against an average of $14.2 million.
• Across the five-year window, Cash from Financing Activities surged 14164.1% in 2022 and tumbled 166.67% in 2025, its largest moves.
• Sutro Biopharma's Cash from Financing Activities stood at $506000.0 in 2021, then surged by 2315.22% to $12.2 million in 2022, then slumped by 125.57% to -$3.1 million in 2023, then jumped by 99.23% to -$24000.0 in 2024, then plunged by 166.67% to -$64000.0 in 2025.
• The last three Cash from Financing Activities figures came in at -$64000.0 (Q4 2025), $102000.0 (Q3 2025), and -$60000.0 (Q2 2025), per Business Quant data.